1. Annas GJ. Standard of care. New York: Oxford University Press, 1993;154–159, 164–166, 181–186.

2. Appelbaum PS, Lidz CW, Meisel A. Informed consent: legal theory and clinical practice. New York: Oxford University Press, 1987.

3. Appelbaum PS, Roth LH. Patients who refuse treatment in medical hospitals. JAMA 1983;250:1296–1301.

4. Barnard D. Unsung questions of medical ethics. Soc Sci Med 1985;21:243–249.

5. Beauchamp TL, Childress JF. Principles of biomedical ethics. 3rd ed. New York: Oxford University Press, 1989.

6. Billings P, et al. Discrimination as a consequence of genetic testing. Am J Hum Genet 1992;51(4):899–901.

7. Canterbury v. Spence. 464 F.2d 772, 1972.

8. Emmitt RJ. Tardy compassion [Letter]. Lancet 1993;341:1157– 1158.

9. Epstein AN. Changes in the delivery of care under comprehensive health care reform. N Engl J Med 1993;329:1672–1676.

10. Fisher M, ed. U.S. Preventive Services Task Force. Guide to clinical preventive services; an assessment of the effectiveness of 169 interventions. Baltimore: Williams & Wilkins, 1989.

11. Folstein S. Huntington disease. Baltimore: Johns Hopkins University Press, 1989;177–187.

12. Forrow L, Arnold RM, Parker LS. Preventive ethics: expanding the horizons of clinical ethics. J Clin Ethics 1993;4:287–294.

13. Fost N. Genetic diagnosis and treatment. AJDC 1993;146:1190–1195.

14. Friedman M. Care and context in moral reasoning. In: Kittay EF, Meyers DT, eds. Women and moral theory. Totowa, NJ: Rowman & Littlefield, 1987.

15. Frye M. The politics of reality: essays in feminist theory. Trumansburg, NY: Crossing Press, 1983.

16. Gelehrter T, Collins F. Principles of medical genetics. Baltimore: Williams & Wilkins, 1990;289–297.

17. Harper P. Research samples from families with genetic diseases: a proposed code of conduct. Br Med J 1993;306:1391–1394.

18. Harper P. Clinical consequences of isolating the gene for Huntington's disease. Br Med J 1993;307:397–398.

19. Hasty compassion [Editorial]. Lancet 1993;341:663.

20. Healy B. Remarks for the RAC committee meeting of January 14, 1993, regarding compassionate use exemption. Hum Gene Ther 1993;4:196–197.

21. Jennings B. Bioethics and democracy. Centennial Rev 1990; 35(2):207–225.

22. Journal of the American Medical Association. Special Issue: Caring for the Uninsured and Underinsured JAMA 1993;265:2437–2624.

23. Kaback MM, Zeiger RS. The John Kennedy Institute Tay Sachs Program: practical and ethical issues in an adult genetic screening program. In: Condliffe P, Callanhan D, Hilton B, eds. Ethical issues in genetic counseling and the use of genetic knowledge. New York: Plenum Press, 1972.

24. Murray T. Ethical issues in human genome research. FASEB 1991;5:55–60.

25. National Society of Genetic Counselors. Code of ethics. Wallingford, PA, 1992.

26. Parker L. Bioethics for human geneticists: models for reasoning and methods for teaching. Am J Hum Genet 1994;54:137–147. [Portions of this chapter have appeared previously in this article.]

27. Payer L. Medicine and culture. New York: Henry Holt and Company, 1988.

28. Pincoffs E. Quandary ethics. Mind 1971;80:552–571.

29. Position paper on human germ line manipulation presented by Council for Responsible Genetics, Human Genetic Committee, Fall 1992. Hum Gene Ther 1993;4:35–37.

30. In the matter of Karen Quinlan. 70 NJ 10, 1976.

31. Ramsey P. The patient as person. New Haven: Yale University Press, 1970.

32. Robinson A, Linden M. Clinical genetic handbook. 2nd ed. Boston: Blackwell Scientific Publications, 1993;465–469.

33. Sherwin SS. No longer patient: feminist ethics and health care. Philadelphia: Temple University Press, 1992.

34. Shore D, Berg K, Wynne O, Folstein MF. Legal and ethical issues in psychiatric genetic research. Am J Med Gen 1993;48(1):17–21.

35. Starr P. The framework of health care reform. N Engl J Med 1993;329:1666–1672.

36. Thompson L. Harkin seeks compassionate use of unproven treatments. Science 1992;258:1728.

37. Thompson L. Healy approves an unproven treatment. Science 1993;259:172.

38. Tsuang MT, Faraone SV. Neuropsychiatric genetics: a new specialty section of the American Journal of Medical Genetics [Editorial]. Am J Med Genet 1993;48(1):1–3.

39. Veatch RM. Models for ethical medicine in a revolutionary age. Hastings Center Rep 1972;2(3):5–7.

40. Walters L. Human gene therapy: ethics and public policy. Hum Gene Ther 1991;2:115–122.

41. Wilfond BS, Fost N. The introduction of cystic fibrosis carrier screening into clinical practice: policy considerations. Milbank Q 1992;70(4):629–59.

42. Wilfond BS, Nolan K. National policy development for the clinical application of genetic diagnostic technologies. Lessons from cystic fibrosis. JAMA 1993;270(24):2948–2954.

43. Wivel N, Walters, L. Germ line gene modification and disease prevention: some medical and ethical perspectives. Science 1993;262:533–538.

44. Yesley MS. Bibliography: ethical legal and social implications of the human genome project. U.S. Department of Energy, Washington, DC, 1992.